Skip to main content
U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.


Secure .gov websites use HTTPS
A lock () or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Table 2a. Therapeutic Management of Nonhospitalized Adults with COVID-19

Last Updated: September 26, 2022

Table 2a. Therapeutic Management of Nonhospitalized Adults With COVID-19
Patient DispositionPanel’s Recommendations
Does Not Require Hospitalization or Supplemental Oxygen For All Patients:
  • All patients should be offered symptom management (AIII).
  • The Panel recommends against the use of dexamethasonea or other systemic corticosteroids in the absence of another indication (AIIb).
For Patients Who Are at High Risk of Progressing to Severe COVID-19b
Preferred therapies. Listed in order of preference:
  • Ritonavir-boosted nirmatrelvir (Paxlovid)c,d (AIIa)
  • Remdesivird,e (BIIa)
Alternative therapies. For use ONLY when neither of the preferred therapies are available, feasible to use, or clinically appropriate. Listed in alphabetical order:
  • Bebtelovimabf (CIII)
  • Molnupiravird,g,h(CIIa)
Discharged From Hospital Inpatient Setting in Stable Condition, Even if Receiving Supplemental OxygenThe Panel recommends against continuing the use of remdesivir (AIIa), dexamethasonea (AIIa), or baricitinib (AIIa) after hospital discharge.
Rating of Recommendations: A = Strong; B = Moderate; C = Weak
Rating of Evidence: I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion